MICROSPHERES FOR IMPROVED BIOAVAILABILITY

微球可提高生物利用度

• 批准号: 2750130
• 负责人: Edith Mathiowitz
• 金额: $ 20万
• 依托单位: BROWN UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 1997
• 资助国家: 美国
• 起止时间: 1997-08-01 至 2001-07-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/2750130
• 关键词: alpha benzopyrone; beta galactosidase; drug design /synthesis /production; gel electrophoresis; gene therapy; high performance liquid chromatography; insulin; laboratory rat; method development; microcapsule; paclitaxel; pharmacokinetics; plasmids; polymers; spectrometry

DESCRIPTION: The investigators propose to develop nanoparticulate biodegradable polymeric oral delivery systems for therapeutic agents representative of hydrophobic small molecules, proteins, and genes, and will study their uptake, as further described by their abstract: "Our project focuses on the development of nanoparticle-based, oral delivery systems, composed of biodegradable polymers, used to efficiently encapsulate and increase the bioavailability and uptake of three representative therapeutic agents from the most active fields of current research: small hydrophobic molecules (taxol), proteins (insulin) and genes. "Although much research has been performed with the first two systems, still there is a challenge to improve the oral bioavailability of these drugs. No product is commercially available on the market, particularly for the oral delivery of peptides and proteins. The last system is the most challenging one, since very little work has been done on oral delivery of genes. "Our hypothesis is that if we succeed in enhancing uptake of drug-loaded nanoparticles, then we may be able to enhance the bioavailability of each of the potential drug candidates. For taxol and insulin, we will target an increase in systemic bioavailability, while for plasmids the nature of he enhancement may be either local or systemic."

描述：研究人员建议开发纳米颗粒 用于治疗剂的可生物降解的聚合物口服递送系统 疏水小分子、蛋白质和基因的代表，并且将 研究他们的吸收，如他们的摘要所进一步描述的： “我们的项目重点是开发基于纳米颗粒的口服给药 由可生物降解的聚合物组成的系统，用于有效地封装 并增加三种代表性药物的生物利用度和吸收 目前研究最活跃领域的治疗药物：小 疏水性分子（紫杉醇）、蛋白质（胰岛素）和基因。 “尽管对前两个系统进行了大量研究， 存在改善这些药物的口服生物利用度的挑战。 没有 产品在市场上可商购获得，特别是用于口服 肽和蛋白质的递送。 最后一个系统最具挑战性 第一，因为口服基因的研究很少。 “我们的假设是，如果我们成功地提高了载药 纳米颗粒，那么我们就可以提高每种药物的生物利用度。 潜在的候选药物。 对于紫杉醇和胰岛素，我们将针对 增加全身生物利用度，而对于质粒， 增强可以是局部的或全身的。"